AbbVie announced accepted abstracts and presentations, including three oral presentations, three poster tours and 25 posters, at the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress. The range of data accepted for presentation showcases AbbVie's commitment to discovering and delivering diverse and innovative solutions for the management of rheumatic diseases. The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually.

"For more than two decades, AbbVie has helped to raise the bar in the care of patients with rheumatic diseases to help patients control their disease and inhibit disease progression," said Chiedzo Mpofu, MBChB, Ph.D., vice president, Global Medical Affairs, Immunology, AbbVie. "We continue that legacy of our scientific ambition as evidenced by the research we are presenting at this year's EULAR Congress, which showcases AbbVie's relentless pursuit of innovation and our aspiration to help eliminate the burden of rheumatic disease for patients."

Key data to be presented include:

SELECT-AXIS 2 trial results that were submitted in regulatory filings for upadacitinib (Rinvoq) in the U.S. and Europe. The trial evaluated the efficacy and safety of upadacitinib in patients with non-radiographic axial spondyloarthritis (nr-axSpA) and in patients with active ankylosing spondylitis (AS) with an inadequate response to bDMARDs (bDMARD-IR)

Results from the impact of treatment with RINVOQ vs HUMIRA (adalimumab) on RAPID3 in patients in SELECT-PsA 1

Two-year data from the SELECT-PsA 1 and SELECT-PsA 2 studies of RINVOQ in patients with psoriatic arthritis (PsA)

Results of the one-year data evaluating the efficacy and safety of SKYRIZI (risankizumab) in patients with active PsA in KEEPsAKE 1 and KEEPsAKE 2

Efficacy and safety results from several rheumatoid arthritis studies of RINVOQ in different patient populations, including the Phase 2 long-term BALANCE-EXTEND and Phase 3 SELECT-COMPARE studies in patients with an inadequate response to methotrexate (MTX-IR), and the SELECT-BEYOND and SELECT-CHOICE studies in bDMARD-IR patients